BioNexus Gene Lab Corp. (NASDAQ:BGLC – Get Free Report) saw a large growth in short interest in the month of July. As of July 15th, there was short interest totalling 224,800 shares, a growth of 19.0% from the June 30th total of 188,900 shares. Based on an average trading volume of 160,500 shares, the days-to-cover ratio is presently 1.4 days. Currently, 2.9% of the shares of the company are sold short.
Institutional Trading of BioNexus Gene Lab
A hedge fund recently raised its stake in BioNexus Gene Lab stock. Virtu Financial LLC increased its stake in shares of BioNexus Gene Lab Corp. (NASDAQ:BGLC – Free Report) by 79.9% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 47,037 shares of the company’s stock after purchasing an additional 20,888 shares during the period. Virtu Financial LLC owned 0.27% of BioNexus Gene Lab worth $33,000 as of its most recent SEC filing. 18.85% of the stock is owned by institutional investors and hedge funds.
BioNexus Gene Lab Stock Down 3.1 %
Shares of BGLC stock traded down $0.02 on Friday, hitting $0.49. 51,409 shares of the stock were exchanged, compared to its average volume of 122,678. BioNexus Gene Lab has a one year low of $0.31 and a one year high of $3.87. The firm’s 50 day moving average is $0.49 and its two-hundred day moving average is $0.60.
About BioNexus Gene Lab
BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers.
Featured Articles
- Five stocks we like better than BioNexus Gene Lab
- Dividend Capture Strategy: What You Need to Know
- Is Crypto Cool Again? What Stocks You Should Be Watching
- 3 Healthcare Dividend Stocks to Buy
- Why Call Options Volume for These 2 Stocks Spiked Together
- The 3 Best Fintech Stocks to Buy Now
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for BioNexus Gene Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNexus Gene Lab and related companies with MarketBeat.com's FREE daily email newsletter.